目的 探讨注射用重组人白细胞介素-12(recombinant human interleukin-12,rhIL-12)同步干预肿瘤放射外科治疗及晚期姑息治疗患者,观察用药后对机体造血功能、全血细胞、免疫功能及辐射防护功能的影响。方法 53例接受射波刀治疗的肿瘤患者,分别为150 ng/kg组19例,250 ng/kg组24例,对照组10例。47例接受晚期姑息治疗的肿瘤患者,其中150 ng/kg组20例,250 ng/kg组21例,对照组6例,治疗当天同步给药,连续观察4周,观察治疗的量效关系。结果 rhIL-12干预后两组患者的造血功能、全血细胞、机体免疫调节、抗辐射损伤等均有改善趋势。有19例首次给药后发热,9例周身不适,2例出现转氨酶和胆红素轻度升高,余无其他不良事件。结论 rhIL-12同步干预肿瘤放射外科、晚期肿瘤姑息治疗,具有显著的联合增益作用,对造血功能抑制、机体免疫紊乱、辐射损伤防治具有较好的改善作用。
Abstract
Objective To investigate the effect of rhIL-12 on the hemopoietic function, immune function, radiation protection function and tumor evaluation indexes in the tumor radiotherapy group and advanced palliative treatment group.Methods There were 53 cases of tumor patients treated with Cyber knife in treatment group, including 19 cases of 150 ng/kg, 24 cases of 250 ng/kg, and 10 cases of control. There were 47 cases of cancer patients in advanced palliative treatment group, including 20 cases of 150 ng/kg, 21 cases of 250 ng/kg, and 6 cases of control. rhIL-12 was given on the day of treatment and the therapeutic effect was observed for 4 consecutive weeks. The dose-effect relationship was studied.Results RhIL-12 could significantly inhibit the decline of blood cells, prevent immune disorders and reduce radiation injury in the two groups. After the first-dose, there were 19 cases of fever, 9 cases of discomfor, 2 cases of slight changes in serum aminotransferase and bilirubin. There was no other adverse event.Conclusions rhIL-12 may be a safe and effective drug for cancer prevention and treatment in clinical practice.
关键词
rhIL-12 /
放射外科 /
晚期肿瘤 /
防治研究
Key words
rhIL-12 /
radiosurgery /
advanced tumor /
research
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Floros T, Tarhini A A. Anticancer cytokines: biology and clinical effects of IFN-γ2, IL-2, IL-15, IL-21, and IL-12[J]. Semin Oncol, 2015, 42(4): 539-548.
[2] 熊国林,赵 毅,邢 爽,等. rhIL-12对恒河猴造血系统辐射防护作用的初步研究[J]. 中国实验血液学杂志, 2013, 21(1): 150-154.
[3] Watford W T, Moriguchi M, Morinobu A, et al. The biology of IL-12: coordinating innate and adaptive immune responses[J]. Cytokine Growth Fact Rev, 2003, 14(5): 361-368.
[4] Dowell A C, Oldham K A, Bhatt R I, et al. Long-term proliferation of functional human NK Cells, with conversion of CD56 (dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12[J]. Cancer Immunol Immunother, 2012, 61(5): 615-628.
[5] Smyth M J, Taniguchi M, Street S E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent[J]. J Immunol, 2000, 165(5): 2665-2670.
[6] Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity[J]. Nature Reviews Immunol, 2003, 3(2): 133-146.
[7] Chen T, Burke K A, Zhan Y, et al. IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation[J]. Exp Hematol, 2007, 35: 203-213.
[8] Basile L A, Ellefson D, Gluzman-Poltorak Z, et al. HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates[J]. PLos One, 2012, 7(2): e30434.
[9] Gerber S A, Cummings R J, Judge J L, et al. Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure[J]. Radiat Res, 2015,183(1): 72-81.
[10] Little R F, Aleman K, Kumar P, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma[J]. Blood, 2007, 110(13): 4165-4171.
[11] Bekaii-Saab T S, Roda J M, Guenterberg K D, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies[J]. Mol Cancer Ther, 2009, 8(11): 2983-2991.
[12] Lenzi R, Edwards R, June C, et al. Phase II study of intraperitoneal recombinant interleukin-12(rhIL-12) in patients with peritoneal carcinomatosis(residual disease<1 cm) associated with ovarian cancer or primary peritoneal carcinoma[J]. J Transl Med, 2007, 5: 66.
[13] Lacy M Q, Jacobus S, Blood E A, et al. Phase II study of interleukin-12 for treament of plateau phase multiple myeloma(E1A96): a trial of the Eastern Cooperative Oncology Group[J]. Leuk Res, 2009, 33(11): 1485-1489.
[14] Gollob J A, Mier J W, Veenstra K,et al.Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN- induction is associated with clinical response[J]. Clin Cancer Res, 2000, 6(5): 1678-1692.
[15] Carreo V,Zeuzem S,Hopf U,et al.A phase Ⅰ/Ⅱ study of recombinant human interleukin-12 in patients with chronic hepatitis B[J]. J Hepatology, 2000, 32(2): 317-324.
[16] Jackson J D, Yan Y, Brunda M J, et al. Interleukin-12 enhances peripheral hematopoiesis in vivo[J]. Blood, 1995, 85(9): 2371-2376.
基金
吴阶平医学基金会重大专项(320.6750.14204)
PDF(5342 KB)
